Skip to main content
Novartis
language-selector-globe
Choose Location
  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
Argentina | Español
Brazil | Português
Canada | English
Canada | Français
Andean & CAC | Español
Colombia | Español
Mexico | Español
United States | English
Australia | English
Hong Kong S.A.R. | 繁體中文
India | English
Indonesia | English
Japan | 日本語
Korea | 한국어
Mainland China | 中文
Malaysia | English
Philippines | English
Singapore | English
Taiwan | 繁體中文
Thailand | ภาษาไทย
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Bulgaria | Български
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hungary | Magyar
Ireland | English
Italy | Italiano
Latvia | Latvian
Lithuania | Lithuanian
Netherlands | Nederlands
Norway | Norsk
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Serbia | Srpski
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Türkiye | Türkçe
Ukraine | українська
United Kingdom | English
Global | English
Novartis Foundation | English
Egypt | English
Israel | עברית
Saudi Arabia | العربية
South Africa | English
language-selector-globe
Choose Location
Americas Asia Pacific Europe International Middle East & Africa
Argentina | Español
Australia | English
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Brazil | Português
Bulgaria | Български
Canada | English
Canada | Français
Andean & CAC | Español
Colombia | Español
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Egypt | English
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hong Kong S.A.R. | 繁體中文
Hungary | Magyar
India | English
Indonesia | English
Ireland | English
Israel | עברית
Italy | Italiano
Japan | 日本語
Korea | 한국어
Latvia | Latvian
Lithuania | Lithuanian
Mainland China | 中文
Malaysia | English
Mexico | Español
Netherlands | Nederlands
Norway | Norsk
Global | English
Novartis Foundation | English
Philippines | English
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Saudi Arabia | العربية
Serbia | Srpski
Singapore | English
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
South Africa | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Taiwan | 繁體中文
Thailand | ภาษาไทย
Türkiye | Türkçe
Ukraine | українська
United Kingdom | English
United States | English
    • About 
      • Novartis in the UK 
      • Partnerships 
        • Collaborative working 
        • External funding 
        • Patient group partnership 
      • Sponsorships 
      • Diseases 
      • Strategy 
      • People and culture 
      • Who we are 
      01077_144dpi_16by9_PPT_RGB
      About
    • Patients and caregivers 
      • External funding 
      • Patient group partnership 
      Doctor and Patient
      Patients and Caregivers
    • Healthcare professionals 
      • For UK healthcare professionals 
      Healthcare Professional Writing
      Healthcare Professionals
    • ESG 
      • Ethical behaviour 
        • Code of Ethics 
        • Speakup 
      • Ethics, risk and compliance 
      • Access 
      • Environmental sustainability 
      • Global health 
      • Transparency 
        • Healthcare professional payment transparency 
      Young girl in doctor's office
      ESG
    • News 
      • Stories 
      • News archive 
      • Novartis UK press office 
      colleagues in discussion
      News
    • Careers 
      • Career search 
      • Personal growth 
      • Early talent 
      • How we work 
      • Well-being 
      • Career programmes 
      • Awards and recognition 
      Business person with a whiteboard behind them in a modern office
      Careers
    • Contact 
    Home
    Home
Header
 

PSC register

PSC REGISTER OF PEOPLE WITH SIGNIFICANT CONTROL/RELEVANT LEGAL ENTITY

The Company has not yet completed taking reasonable steps to find out if there is anyone who is a registrable person or a registrable relevant legal entity in relation to the following companies.

With effect from 20 April 2016 the above statement is no longer applicable and the appropriate PSC registers for the following companies are now available:

Advanced Accelerator Applications UK Limited – Company Number 09751912 (198 KB)

Advanced Accelerator Applications (UK & Ireland) Ltd - Company Number 04189193 (22 KB)

Leo Osprey Limited – Company Number 09000270 (69 KB)

NeuTec Pharma Limited – Company Number 03297187 (17 KB)

Novartis UK Limited – Company Number 398071 (17 KB)

Novartis UK Pension Trustees  - Company Number 3417278 (17 KB)

Novartis Pharmaceuticals UK Limited – Company Number 119006 (17 KB)

Novartis Europharm Limited – Company Number 03068306 (17 KB)

Novartis Grimsby Limited – Company Number 170180 (17 KB)

Oriel Therapeutics Limited – Company Number 06694573 (16 KB)

The Medicines Company UK Limited - Company Number 03484279 (22 KB)

Vivacta Limited – Company Number 5397165 (17 KB)

Ziarco Group Limited – Company Number 09248615 (102 KB)

Ziarco Pharma Limited – Company Number 08257024 (102 KB)

Novartis UK

Navigate Novartis
  • Patients and caregivers
  • ESG
  • News
  • Careers
Media Center
  • News archive
  • Stories
Our Portfolio
  • Novartis clinical pipeline
  • Novartis product information
Other Novartis Websites
  • Healthcare Professional portal
  • Novartis global
  • Advanced accelerator applications
  • Novartis biome
  • Novartis clinical trials
Footer Bottom
© 2025 Novartis Pharmaceuticals UK Ltd
  • Privacy policy
  • Terms of use
  • Contact
  • Web accessibility
  • Modern slavery statement
  • Cookie settings
Novartis Site Directory
This site is intended for an audience in the UK